Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 3/20 | 0.70 |
| ▸ | OGG1 | O15527 | 1/20 | 0.59 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | C1R | P00736 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14262930 | 0.78 | PDE5A (0.85) | PDE5AOGG1NPY5RALDH1A1SMN1; SMN2 | |
| SCHEMBL14262923 | 0.76 | PDE5A (0.82) | PDE5AOGG1NPY5RALDH1A1SMN1; SMN2 | |
| SCHEMBL4836360 | 0.76 | PDE5A (0.60) | PDE5AOGG1ALDH1A1ADORA3TMEM97 | |
| SCHEMBL13356962 | 0.76 | PDE5A (0.60) | PDE5AOGG1ALDH1A1ADORA3TMEM97 | |
| SCHEMBL786840 | 0.75 | PDE5A (0.62) | PDE5AOGG1NPY5RSMN1; SMN2ADORA3 | |
| SCHEMBL4095293 | 0.74 | PDE5A (1.00) | PDE5AOGG1ALDH1A1RAD52 | |
| SCHEMBL4856833 | 0.73 | PDE5A (0.64) | PDE5AOGG1NPY5RALDH1A1SMN1; SMN2 | |
| SCHEMBL4867110 | 0.73 | PDE5A (0.70) | PDE5AOGG1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL28054407 | 0.73 | PDE5A (0.63) | PDE5AOGG1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4085200 | 0.72 | PDE5A (1.00) | PDE5AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| WO-2008157500-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | CNR2, CNR1, GPR18 | PDE5A 1861/4885OGG1 2592/4885NPY5R 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.